Arthur Klausner
Direktor/Vorstandsmitglied bei MONOPAR THERAPEUTICS INC.
Vermögen: 19 351 $ am 30.04.2024
Aktive Positionen von Arthur Klausner
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MONOPAR THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.08.2017 | - |
Independent Dir/Board Member | 01.08.2017 | - | |
Cennerv Pharmaceuticals Ltd.
Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Direktor/Vorstandsmitglied | 31.07.2015 | - |
Delphinus Therapeutics, Inc. | Vorstandsvorsitzender | 01.01.2018 | - |
Präsident | 01.01.2018 | - | |
Amyriad Therapeutics, Inc.
Amyriad Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Amyriad Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. Amyriad Therapeutics, Inc. focuses on developing therapies for the relief of Alzheimer's disease symptoms. The company was founded by Christian Angermayer, Thomas Hanke, Anil K. Ratty, Marlon Braumann. The CEO is Sharon L. Rogers. | Direktor/Vorstandsmitglied | - | - |
Concarlo Holdings LLC
Concarlo Holdings LLC Miscellaneous Commercial ServicesCommercial Services Concarlo Holdings LLC operates as a biotechnology firm. It specializes in drug development. The company was founded by Stacy Blain and LisaMarie Casey and is headquartered in Brooklyn, NY. | Vorsitzender | - | - |
Karriereverlauf von Arthur Klausner
Ehemalige bekannte Positionen von Arthur Klausner
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Goldilocks Therapeutics, Inc.
Goldilocks Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Goldilocks Therapeutics, Inc. engages in the development of drug delivery technology for kidney tubules. It offers treatment for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs). The company was founded by Arthur J. Klausner, Daniel A. Heller, and Edgar A. Jaimes in 2018 and is headquartered in Bedford, NY. | Direktor/Vorstandsmitglied | 01.01.2018 | 01.01.2022 |
Vorstandsvorsitzender | 01.01.2018 | 01.01.2022 | |
Gründer | 01.01.2018 | 01.01.2022 | |
Präsident | 01.01.2018 | 01.01.2022 | |
Gem Pharmaceuticals LLC
Gem Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Gem Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company that develops anthracycline derivatives used to eliminate cardiotoxicity side effect in chemotherapeutics. The company is headquartered in Birmingham, AL. | Direktor/Vorstandsmitglied | 01.01.2012 | 01.01.2017 |
Vorstandsvorsitzender | 01.01.2012 | 01.01.2017 | |
Jade Therapeutics, Inc.
Jade Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., Jade Therapeutics, Inc. develops pharmaceutical products. The company is based in Salt Lake City, UT. The company was founded by Barbara Wirostko. Jade Therapeutics was acquired by Kiora Pharmaceuticals, Inc. on March 07, 2016 for $5.10 million. | Vorstandsvorsitzender | 01.01.2012 | 01.12.2015 |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | 01.01.2005 | 30.04.2009 |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Ausbildung von Arthur Klausner
Princeton University | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 15 |
2 | |
Singapur | 2 |
Operativ
Director/Board Member | 10 |
Chief Executive Officer | 4 |
President | 2 |
Sektoral
Health Technology | 9 |
Commercial Services | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 13 |
---|---|
Santarus, Inc.
Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Health Technology |
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
Gentis, Inc.
Gentis, Inc. Medical SpecialtiesHealth Technology Gentis, Inc. engages in the development and testing technologies for the minimally invasive treatments. The company was founded by Charles Cohen and Paul Ducheyne in 2000 and is headquartered in Wayne, PA. | Health Technology |
Gem Pharmaceuticals LLC
Gem Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Gem Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company that develops anthracycline derivatives used to eliminate cardiotoxicity side effect in chemotherapeutics. The company is headquartered in Birmingham, AL. | Health Technology |
Jade Therapeutics, Inc.
Jade Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kiora Pharmaceuticals, Inc., Jade Therapeutics, Inc. develops pharmaceutical products. The company is based in Salt Lake City, UT. The company was founded by Barbara Wirostko. Jade Therapeutics was acquired by Kiora Pharmaceuticals, Inc. on March 07, 2016 for $5.10 million. | Health Technology |
Monopar Therapeutics, Inc. | |
Cennerv Pharmaceuticals Ltd.
Cennerv Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore. | Health Technology |
Concarlo Holdings LLC
Concarlo Holdings LLC Miscellaneous Commercial ServicesCommercial Services Concarlo Holdings LLC operates as a biotechnology firm. It specializes in drug development. The company was founded by Stacy Blain and LisaMarie Casey and is headquartered in Brooklyn, NY. | Commercial Services |
Delphinus Therapeutics, Inc. | |
Goldilocks Therapeutics, Inc.
Goldilocks Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Goldilocks Therapeutics, Inc. engages in the development of drug delivery technology for kidney tubules. It offers treatment for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs). The company was founded by Arthur J. Klausner, Daniel A. Heller, and Edgar A. Jaimes in 2018 and is headquartered in Bedford, NY. | Commercial Services |
Amyriad Therapeutics, Inc.
Amyriad Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Amyriad Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. Amyriad Therapeutics, Inc. focuses on developing therapies for the relief of Alzheimer's disease symptoms. The company was founded by Christian Angermayer, Thomas Hanke, Anil K. Ratty, Marlon Braumann. The CEO is Sharon L. Rogers. | Health Technology |
- Börse
- Insiders
- Arthur Klausner
- Erfahrung